Dietary treatment of nonalcoholic steatohepatitis

Current Opinion in Gastroenterology

Volumn 29, Issue 2, 2013, Pages 170-176

  Perito, Emily R ^a   Rodriguez, Luis A ^b   Lustig, Robert H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fructose; lipotoxicity; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; trans fat

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; CARBOHYDRATE; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; CATHEPSIN B; FRUCTOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; PATATIN LIKE PHOSPHOLIPASE 3; PHOSPHOLIPASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SIRTUIN 3; SUGAR; TOLL LIKE RECEPTOR 4; TRANS FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; AEROBIC EXERCISE; AFRICAN AMERICAN; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEVERAGE; CALORIC RESTRICTION; CARBOHYDRATE DIET; CAUCASIAN; DIET THERAPY; ETHNIC DIFFERENCE; FAST FOOD; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY LIVER; FRUIT JUICE; GENETIC POLYMORPHISM; GLYCEMIC INDEX; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID DIET; LIPOLYSIS; LIPOTOXICITY; LIVER FIBROSIS; LIVER MITOCHONDRION; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; LYSOSOME; MACRONUTRIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

DIETARY CARBOHYDRATES; FATTY LIVER; FRUCTOSE; HUMANS; MODELS, BIOLOGICAL; TRANS FATTY ACIDS; WEIGHT LOSS;

EID: 84873405891     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835ca11d     Document Type: Review

References (71)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40:1387-1395.
2. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118:1388-1393.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 142:1592-1609.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
5. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141:1249-1253.
6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
7. Day CP, James OF. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114:842-845.
8. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52:774-788.
9. Bass NM. Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic. Hepatology 2010; 51:4-7.
10. Fuchs M, Sanyal AJ. Lipotoxicity in NASH. J Hepatol 2012; 56:291-293.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
12. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106:15430-15435.
13. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, lowcarbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77:43-50.
14. Le KA, Ith M, Kreis R, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009; 89:1760-1765.
15. Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis 2010; 5:24.
16. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56:1145-1151.
17. Bambha K, Belt P, Abraham M, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55:769-780.
18. Schwimmer JB, McGreal N, Deutsch R, et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115:e561-e565.
19. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
20. Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52:1281-1290.
21. Davis JN, Le KA, Walker RW, et al. Increased hepatic fat in overweight hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010; 92:1522-1527.
22. Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464: 121-125.
23. Gao Z, Zhang J, Kheterpal I, et al. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem 2011; 286:22227-22234.
24. Kechagias S, Ernersson A, Dahlqvist O, et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008; 57:649-654.
25. Sobrecases H, Le KA, Bortolotti M, et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab 2010; 36:244-246.
26. Kohli R, Kirby M, Xanthakos SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52:934-944.
27. Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295:G987-G995.
28. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
29. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of nonalcoholic fatty liver disease in adults: A systematic review. J Hepatol 2012; 56:255-266.
30. Peng L, Wang J, Li F. Weight reduction for nonalcoholic fatty liver disease. Cochrane Database Syst Rev 2011:CD003619.
31. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut 2011; 60:1278-1283.
32. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50:1105-1112.
33. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33:2156-2163.
34. Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with nonalcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009; 94:437-442.
35. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51:121-129.
36. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49:80-86.
37. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008; 48:119-128.
38. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011; 53:1504-1514.
39. de Luis DA, Aller R, Izaola O, et al. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 2010; 25:730-735.
40. Kirk E, Reeds DN, Finck BN, et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136:1552-1560.
41. Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012; 96:727-734.
42. Ryan MC, Abbasi F, Lamendola C, et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007; 30:1075-1080.
43. Fraser A, Abel R, Lawlor DA, et al. A modified mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: Results of a quasi-randomised controlled trial. Diabetologia 2008; 51:1616-1622.
44. Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012; 129:557-570.
45. Park YK, Yetley EA. Intakes and food sources of fructose in the United States. Am J Clin Nutr 1993; 58 (Suppl 5):737SY747S.
46. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr 2009; 139:1228S-1235S.
47. Vos MB, Kimmons JE, Gillespie C, et al. Dietary fructose consumption among US children and adults: The third national health and nutrition examination survey. Medscape J Med 2008; 10:160.
48. Johnson RK, Appel LJ, Brands M, et al. Dietary sugars intake and cardiovascular health: A scientific statement from the American Heart Association. Circulation 2009; 120:1011-1020.
49. Stanhope KL, Griffen SC, Bair BR, et al. Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr 2008; 87:1194-1203.
50. Stanhope KL, Bremer AA, Medici V, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 2011; 96:E1596-E1605.
51. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): A population based study. J Hepatol 2007; 47:711-717.
52. Maersk M, Belza A, Stodkilde-Jorgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study. Am J Clin Nutr 2012; 95:283-289.
53. Havel PJ. Dietary fructose: Implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005; 63:133-157.
54. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010; 90:23-46.
55. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr 1996; 16:523-557.
56. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119:1322-1334.
57. Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab 2011; 96:861-868.
58. Samuel VT. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab 2011; 22:60-65.
59. Cox CL, Stanhope KL, Schwarz JM, et al. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 2012; 66:201-208.
60. Jin R, Le NA, Liu S, et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 2012; 97:E1088-E1098.
61. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1961-1971.
62. Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol 2010; 21:247-252.
63. Larter CZ, Yeh MM. Animal models of NASH: Getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23:1635-1648.
64. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90:2804-2809.
65. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med 2006; 354:1601-1613.
66. Allison DB, Egan SK, Barraj LM, et al. Estimated intakes of trans fatty and other fatty acids in the US population. J Am Diet Assoc 1999; 99:.
67. Doell D, Folmer D, Lee H, et al. Updated estimate of trans fat intake by the US population. Food Addit Contam Part A Chem Analysis Control Expo Risk Assess 2012; 29:861-874.
68. Micha R, Mozaffarian D. Trans fatty acids: Effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 2009; 5:335-344.
69. Machado RM, Stefano JT, Oliveira CP, et al. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 2010; 140:1127-1132.
70. Neuschwander-Tetri BA, Ford DA, Acharya S, et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012; 47:941-950.
71. Angelieri CT, Barros CR, Siqueira-Catania A, Ferreira SR. Trans fatty acid intake is associated with insulin sensitivity but independently of inflammation. Braz J Med Biol Res 2012; 45:625-631.